Literature DB >> 17540548

Oral low molecular weight heparin delivery by microparticles from complex coacervation.

Alf Lamprecht1, Nathalie Ubrich, Philippe Maincent.   

Abstract

As low molecular weight heparins exhibit limited oral absorption they usually have to be administered parenterally. Their strong negative charge appears to be one of the biggest hurdles to overcome in order to increase oral absorption. Complex coacervation has been proposed as a microencapsulation technique for increased oral drug absorption on the basis of charge compensation. Optimized tinzaparin/acacia gum mixture were coacervated with either gelatin A or B leading to microparticles with monodispersed size distribution, good fluidity and high encapsulation rates (>90%), while mean particle size varied between 5 and 20 microm, respectively, depending on the gelatin type. Tinzaparin was homogeneously distributed throughout the particle matrix and anti-Xa activity was maintained during preparation and storage. Drug release occurred in dependency of the pH triggering the dissociation between tinzaparin/acacia and gelatin. Cell binding experiments on Caco-2 led to slightly increased adhesion of gelatin A microparticles compared to gelatin B (A: 3.5+/-0.3%; B: 2.5+/-0.3%; solution: 1.9+/-0.1%), while drug transport did not differ from free tinzaparin solution. In-vivo results demonstrated an oral bioavailability of about 4.2+/-2.9% with gelatin B particles while gelatin A led to no absorption of tinzaparin. In conclusion, tinzaparin microparticles exhibited excellent particle properties in vitro and demonstrate potential for a formulation increasing the oral bioavailability of low molecular weight heparins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540548     DOI: 10.1016/j.ejpb.2007.04.004

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates.

Authors:  Angela Viehof; Alf Lamprecht
Journal:  Pharm Res       Date:  2013-05-07       Impact factor: 4.200

2.  Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.

Authors:  Alyaa Ramadan; Frederic Lagarce; Anne Tessier-Marteau; Olivier Thomas; Pierre Legras; Laurent Macchi; Patrick Saulnier; Jean Pierre Benoit
Journal:  Int J Nanomedicine       Date:  2011-11-21

Review 3.  Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes.

Authors:  Fahad Akhtar; Xinyu Wan; Gang Wu; Samuel Kesse; Shaoda Wang; Shuying He
Journal:  Molecules       Date:  2018-07-18       Impact factor: 4.411

4.  Development of enoxaparin sodium polymeric microparticles for colon-specific delivery.

Authors:  Dana Hales; Maxime Casteran; Anne Sapin-Minet; Ioan Tomuţa; Marcela Achim; Laurian Vlase; Philippe Maincent
Journal:  Clujul Med       Date:  2015-07-01

Review 5.  Strategies to Overcome Heparins' Low Oral Bioavailability.

Authors:  Ana Rita Neves; Marta Correia-da-Silva; Emília Sousa; Madalena Pinto
Journal:  Pharmaceuticals (Basel)       Date:  2016-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.